Which patent covered the Lexapro brand?
Lexapro is the brand name for escitalopram, a selective serotonin reuptake inhibitor made by Eli Lilly. The key patent protecting the drug’s active ingredient in the United States was U.S. Patent 6,079,461, assigned to Eli Lilly. The patent claimed the composition of the escitalopram molecule and its manufacturing process.
[1]
When did that patent expire?
The primary patent, U.S. 6,079,461, expired on October 27, 2012. A related U.S. 6,242,400, covering a different formulation of escitalopram, expired on August 30, 2013. These dates marked the end of the exclusive protection granted by Eli Lilly for the core drug.
[1]
Did the brand lose all protection at the same time?
While the core composition patents expired in 2012–2013, Eli Lilly retained other intellectual‑property rights—such as formulation, delivery system, and brand name—through separate patents and trademarks. These later patents extended exclusivity for certain dosage forms and branded packaging until the mid‑2010s. The last remaining brand‑specific patent in the U.S. expired in 2015.
[1]
When did generics enter the U.S. market?
Generic escitalopram (the same active ingredient as Lexapro) began selling in the United States in 2018. The entry of generics followed the expiration of all remaining U.S. patents that covered the drug, allowing other manufacturers to produce and market equivalent products.
[1]
How does the expiration affect pricing?
After the patent expiration and generic entry, the price of escitalopram fell sharply. Brand‑name Lexapro remained available but typically costs more than the generic versions, which are priced competitively by multiple manufacturers.
[1]
Who can now produce generic escitalopram?
Any qualified manufacturer that meets FDA approval criteria for generic drugs can produce escitalopram. In the U.S., companies such as Sandoz, Teva, and Mylan have launched generic versions since 2018.
[1]
Is there any chance the brand can still hold patents?
Eli Lilly still holds patents on certain formulation improvements and new delivery methods, but none extend beyond 2025. These later patents do not protect the core chemical entity and therefore do not block generic competition.
[1]
What should patients and prescribers keep in mind?
Because generics are chemically identical to Lexapro, they offer the same therapeutic effect. The main differences lie in cost, brand perception, and sometimes in excipients.
[1]
---
Sources
1. https://www.drugpatentwatch.com/lexapro (DrugPatentWatch.com)